Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE
570 views
October 4, 2024
Chapters
ESMO 2024 Highlights & Early Stage Discussion
00:00
KEYNOTE-522: Pembrolizumab in Triple Negative BC
00:47
I-SPY 2.2: Tailoring Neoadjuvant Treatment
10:13
Ribociclib Insights: NATALEE Updates, Eligibility, Age-Based Outcomes, Adjuvant treatment selection
21:55
Comments 0
Login to view comments.
Click here to Login